Roma Green Finance Limited (ROMA): ROMA...$1.03...With 80,000 bidding at a...

ROMA...$1.03...With 80,000 bidding at a $1...🥳

georgie18 · 2024-10-28T19:59:21.9800000Z

ROMA...$1.03...With 80,000 bidding at a $1...🥳 georgie18 Member Level Re: georgie18 post# 661642 Friday, October 25, 2024 2:13:41 PM Post# 662797 of 663003 ROMA...$1.02s clearing here...🥳 georgie18 Member Level Re: georgie18 post# 61 Friday, October 18, 2024 8:11:44 AM Post# 62 of 63 ROMA...$1.03...🥳Been trying to breakout of the .90s for over a week... georgie18 Member Level Re: georgie18 post# 660643 Wednesday, October 16, 2024 1:43:13 PM Post# 661371 of 661641 ROMA...99...Market Maker MPE...39K on top ask...🥳 clear this and we could go...imo...we shall see... georgie18 Member Level Re: georgie18 post# 59 Tuesday, October 08, 2024 2:22:16 PM Post# 60 of 60 ROMA...91...Red to Green here...🥳 georgie18 Member Level Re: georgie18 post# 659988 Monday, October 07, 2024 11:38:31 AM Post# 660502 of 660642 ROMA...87...🥳...Trying to Break the recent high of .94...off the .48 Bottom... georgie18 Member Level Re: georgie18 post# 57 Wednesday, October 02, 2024 9:13:08 AM Post# 58 of 58 ROMA...91...🥳...Nice Organic move off the .48 range bottom... georgie18 Member Level Re: georgie18 post# 659897 Tuesday, October 01, 2024 3:40:00 PM Post# 659933 of 659987 ROMA...88s clearing here...🥳 georgie18 Member Level Re: georgie18 post# 55 Tuesday, October 01, 2024 11:23:41 AM Post# 56 of 56 ROMA...84...HOD...🥳 georgie18 Member Level Re: georgie18 post# 659786 Tuesday, October 01, 2024 7:57:05 AM Post# 659848 of 659896 ROMA...775...in the P/M...🥳 georgie18 Member Level Re: georgie18 post# 53 Monday, September 30, 2024 12:09:32 PM Post# 54 of 54 ROMA...71...Looking for Triple Top Breakout here with volume...🥳 georgie18 Member Level Re: georgie18 post# 659423 Thursday, September 26, 2024 2:23:01 PM Post# 659494 of 659783 ROMA...70X72 with strong volume for this ticker...🥳 georgie18 Member Level Re: georgie18 post# 51 Thursday, September 26, 2024 10:21:00 AM Post# 52 of 52 ROMA...655...Bullish Psar Flip...Volume coming in here...🥳

Play Episode

6min

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Proactive - Interviews for investors

ACG Metals CFO says hold hedge strategy is already paying off

ACG Metals Ltd chief financial officer Patrick Henze talked with Proactive's Stephen Gunnion about the company’s recently announced gold hedging strategy and its importance during ACG’s transition phase from precious to base metals. Henze explained that while ACG Metals is ultimately targeting copper production from its Gediktepe mine in Turkey by 2026, the mine currently generates strong cash flow from gold and silver. The company has moved to hedge 50% of its gold production at US$2,875 per ounce through January 2026, helping secure revenue in a volatile pricing environment. He noted: “We are currently producing gold and silver, which is a perfect transition for us to become a copper producer in ’26… we can benefit and protect a bit the cash flows by hedging the gold.” The hedge program, executed with Alpha, involves no cash outlay and allows ACG to retain upside exposure above US$3,065 per ounce on the hedged portion. Henze emphasised this strategy helps ACG provide more certainty to bondholders and equity investors by de-risking key financial metrics for 2025. The company remains unhedged on silver and copper, maintaining exposure for future upside. For more updates, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future content. #ACGMetals #GoldHedging #CopperTransition #GediktepeMine #MiningStrategy #GoldPrices #Commodities #CashFlowManagement #MiningInvestment #ProactiveInvestors

Proactive - Interviews for investors

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones

Trevi Therapeutics CEO Jennifer Good joined Steve Darling from Proactive to discuss the company’s progress in advancing its cough treatment pipeline using nalbuphine, a mixed agonist-antagonist opioid. Originally developed for acute indications, nalbuphine is now being repurposed due to its dual mechanism of action, working both peripherally in the lungs and centrally in the brainstem, offering a novel approach to treating chronic cough disorders. Trevi initially explored multiple indications, including skin conditions caused by severe itching and neurological cough. However, compelling clinical data led the company to focus on cough-related indications. Good explained, “We thought our drug was different because not only does it work peripherally in the lung, it works centrally at the brain, which mediates coughing and breathing.” The company is now targeting three key areas: interstitial lung diseases (including idiopathic pulmonary fibrosis, or IPF), refractory chronic cough (RCC), and other neurological cough conditions. Following promising Phase 2a results in RCC—an area where many previous drug candidates have failed—Trevi is preparing for a Phase 2b dose-ranging study. If successful, only one pivotal study may be required before regulatory filing. Good also highlighted Trevi’s strong financial position, noting that the company has sufficient cash runway to support its current studies through the second half of 2026, including further development in RCC and IPF. #proactiveinvestors #trevitherapeuticsinc #nasdaq #trvi #JenniferGood #Nalbuphine #ChronicCough #RefractoryCough #Phase2aResults #BiotechNews #PharmaPipeline #IPF #ClinicalTrials #CoughTreatment #NeurologicalDisorders #ProactiveInvestors

Proactive - Interviews for investors

Oriole Resources wraps up pivotal 2024, targets major gold milestones in 2025

Oriole Resources PLC (AIM:ORR) CEO Martin Rosser and CFO Bob Smeeton take Proactive's Stephen Gunnion through the company’s latest full-year results and upcoming milestones across its key exploration projects. Rosser highlighted a pivotal year for the company’s Bibemi and Mbe gold projects in Cameroon. At Bibemi, a recently completed phase five drilling campaign is feeding into a revised Mineral Resource Estimate (MRE), expected this quarter. “We believe there's very good potential to not just increase the amount of gold, but also improve the category of the resource,” said Rosser. The company is also advancing an exploitation license application for the project. At Mbe, maiden drilling continues, following trenching results that indicated strong mineralisation. “We think Mbe South has significant potential to host a substantial gold deposit,” Rosser added. Smeeton detailed a £2 million reduction in operating loss and financial support from BCM International. “Since year-end, BCM have given us $1.1 million, largely replenishing CapEx,” Smeeton noted. He also confirmed progress on a joint venture agreement with Managem at the Senala project in Senegal. Rosser pointed to potential sector-wide revaluations driven by high gold prices and possible M&A activity. “Oriole’s shares are significantly undervalued,” he said. For more updates from Oriole Resources and other mining sector interviews, give this video a like, subscribe to Proactive’s YouTube channel, and enable notifications so you don’t miss future content. #OrioleResources #GoldExploration #CameroonMining #MbeProject #BibemiGold #JuniorMiners #MiningInvestment #MineralResourceEstimate #GoldPrice #MiningFinance #ProactiveInvestors #ManagemJV #SenalaProject #CameroonGold #ExplorationDrilling

Followers	2254
Posts	103259
Boards Moderated	2
Alias Born	12/17/2011

Volume:	14,535
Day Range:	0.79 - 0.82
Bid:	0.7852
Ask:	0.84
Last Trade Time:	7:07:49 PM EDT
Total Trades:	72

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

ROMA Detailed Quote

Recent ROMA News

More ROMA News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent ROMA News

Go Ad-Free